loading
Schlusskurs vom Vortag:
$15.23
Offen:
$15.17
24-Stunden-Volumen:
396.66K
Relative Volume:
0.46
Marktkapitalisierung:
$1.26B
Einnahmen:
$288.00K
Nettoeinkommen (Verlust:
$-228.06M
KGV:
-3.6871
EPS:
-4.25
Netto-Cashflow:
$-168.82M
1W Leistung:
+7.70%
1M Leistung:
+8.44%
6M Leistung:
-22.39%
1J Leistung:
+27.92%
1-Tages-Spanne:
Value
$14.98
$15.94
1-Wochen-Bereich:
Value
$13.84
$15.94
52-Wochen-Spanne:
Value
$9.90
$27.20

Viridian Therapeutics Inc Stock (VRDN) Company Profile

Name
Firmenname
Viridian Therapeutics Inc
Name
Telefon
617.272.4600
Name
Adresse
221 CRESCENT STREET, WALTHAM
Name
Mitarbeiter
143
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
VRDN's Discussions on Twitter

Vergleichen Sie VRDN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VRDN
Viridian Therapeutics Inc
15.67 1.26B 288.00K -228.06M -168.82M -4.25
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-19 Herabstufung Wells Fargo Overweight → Equal Weight
2024-11-25 Eingeleitet TD Cowen Buy
2024-09-11 Bestätigt Needham Buy
2024-06-11 Eingeleitet Wolfe Research Outperform
2024-06-06 Eingeleitet Goldman Buy
2024-05-09 Herabstufung B. Riley Securities Buy → Neutral
2024-05-09 Herabstufung Ladenburg Thalmann Buy → Neutral
2023-06-14 Eingeleitet BTIG Research Buy
2023-06-14 Fortgesetzt Credit Suisse Outperform
2023-05-30 Eingeleitet RBC Capital Mkts Outperform
2023-04-17 Eingeleitet Wells Fargo Overweight
2023-03-30 Eingeleitet Stifel Buy
2022-12-19 Eingeleitet Cowen Outperform
2022-12-19 Eingeleitet Needham Buy
2022-12-16 Eingeleitet Credit Suisse Outperform
2022-12-01 Eingeleitet H.C. Wainwright Buy
2022-06-23 Eingeleitet B. Riley Securities Buy
2021-11-18 Eingeleitet SVB Leerink Outperform
2021-10-12 Eingeleitet Evercore ISI Outperform
2021-01-25 Eingeleitet Ladenburg Thalmann Buy
Alle ansehen

Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten

pulisher
Jun 17, 2025

When (VRDN) Moves Investors should Listen - news.stocktradersdaily.com

Jun 17, 2025
pulisher
Jun 15, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $37.56 Average Target Price from Analysts - Defense World

Jun 15, 2025
pulisher
Jun 13, 2025

Viridian Therapeutics’ SWOT analysis: promising TED treatment stock faces pivotal year - Investing.com

Jun 13, 2025
pulisher
Jun 11, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by California State Teachers Retirement System - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Viridian Therapeutics: The Song Remains The Same (NASDAQ:VRDN) - Seeking Alpha

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : Viridian Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener

Jun 09, 2025
pulisher
Jun 07, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.22 Million Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Where are the Opportunities in (VRDN) - news.stocktradersdaily.com

Jun 05, 2025
pulisher
Jun 05, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VRDN Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jun 05, 2025
pulisher
Jun 04, 2025

Viridian Therapeutics shares fall as Q1 loss narrows, revenue beats By Investing.com - Investing.com Nigeria

Jun 04, 2025
pulisher
Jun 02, 2025

Ameriprise Financial Inc. Increases Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Jun 02, 2025
pulisher
May 30, 2025

Viridian Therapeutics to Participate in Upcoming June 2025 Investor Conferences - BioSpace

May 30, 2025
pulisher
May 30, 2025

Viridian Therapeutics to Participate in Upcoming June Investor C - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Viridian Therapeutics to Participate in Upcoming June Investor Conferences - Business Wire

May 30, 2025
pulisher
May 29, 2025

Bank of America Corp DE Grows Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

May 29, 2025
pulisher
May 27, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 13,990 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

May 27, 2025
pulisher
May 27, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Holdings Increased by Nuveen Asset Management LLC - Defense World

May 27, 2025
pulisher
May 27, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by Millennium Management LLC - Defense World

May 27, 2025
pulisher
May 22, 2025

Needham & Company LLC Reiterates “Buy” Rating for Viridian Therapeutics (NASDAQ:VRDN) - Defense World

May 22, 2025
pulisher
May 21, 2025

Viridian Therapeutics’ veligrotug shows durability in Phase III TED trial - Yahoo Finance

May 21, 2025
pulisher
May 21, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $36.70 Average Target Price from Analysts - Defense World

May 21, 2025
pulisher
May 20, 2025

Veligrotug Shows Durability for Thyroid Eye Disease in Phase 3 Trial Results - HCPLive

May 20, 2025
pulisher
May 20, 2025

Viridian Therapeutics’ SWOT analysis: promising TED treatment stock faces key catalysts - Investing.com Nigeria

May 20, 2025
pulisher
May 20, 2025

Viridian Therapeutics (VRDN) Maintains Stable Outlook with Buy Rating | VRDN Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Viridian Therapeutics: Buy Rating Affirmed on Promising Phase III Results and Strategic Growth Plans - TipRanks

May 20, 2025
pulisher
May 20, 2025

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) - BioSpace

May 20, 2025
pulisher
May 20, 2025

Viridian Therapeutics Announces Positive Long-Term Durability Da - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Viridian's (VRDN) Veligrotug Shows Promising Long-Term Results in TED Treatment | VRDN Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Viridian Announces Positive Long-Term Data From Phase 3 Trial Of Veligrotug In Thyroid Eye Disease - Nasdaq

May 20, 2025
pulisher
May 20, 2025

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) | VRDN Stock News - GuruFocus

May 20, 2025
pulisher
May 16, 2025

Northern Trust Corp Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

May 16, 2025
pulisher
May 16, 2025

Dimensional Fund Advisors LP Sells 271,156 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

May 16, 2025
pulisher
May 15, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by The Manufacturers Life Insurance Company - Defense World

May 15, 2025
pulisher
May 12, 2025

Viridian Therapeutics (VRDN) to Release Quarterly Earnings on Wednesday - Defense World

May 12, 2025
pulisher
May 10, 2025

Q2 EPS Estimate for Viridian Therapeutics Lowered by Analyst - Defense World

May 10, 2025
pulisher
May 10, 2025

Wedbush Boosts Earnings Estimates for Viridian Therapeutics - Defense World

May 10, 2025
pulisher
May 10, 2025

Q2 EPS Estimate for Viridian Therapeutics Reduced by Analyst - Defense World

May 10, 2025
pulisher
May 10, 2025

B. Riley Boosts Earnings Estimates for Viridian Therapeutics - Defense World

May 10, 2025
pulisher
May 10, 2025

Needham & Company LLC Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00 - The AM Reporter

May 10, 2025
pulisher
May 10, 2025

JMP Securities Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $38.00 - Defense World

May 10, 2025
pulisher
May 10, 2025

Royal Bank of Canada Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $45.00 - Defense World

May 10, 2025
pulisher
May 09, 2025

Q1 Earnings Estimate for VRDN Issued By HC Wainwright - Defense World

May 09, 2025
pulisher
May 09, 2025

The Goldman Sachs Group Issues Pessimistic Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - Defense World

May 09, 2025
pulisher
May 09, 2025

Needham & Company LLC Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00 - Defense World

May 09, 2025
pulisher
May 08, 2025

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) - BioSpace

May 08, 2025
pulisher
May 08, 2025

Decoding Viridian Therapeutics Inc (VRDN): A Strategic SWOT Insi - GuruFocus

May 08, 2025
pulisher
May 07, 2025

What 5 Analyst Ratings Have To Say About Viridian Therapeutics - Benzinga

May 07, 2025
pulisher
May 07, 2025

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 07, 2025
pulisher
May 07, 2025

FDA Grants Breakthrough Therapy Status to Viridian's (VRDN) Veligrotug | VRDN Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) | VRDN Stock News - GuruFocus

May 07, 2025

Finanzdaten der Viridian Therapeutics Inc-Aktie (VRDN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Viridian Therapeutics Inc-Aktie (VRDN) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Fairmount Funds Management LLC
Director
Jun 09 '25
Option Exercise
7.80
1,600
12,480
3,447,413
Beetham Thomas W.
Chief Operating Officer
Sep 27 '24
Buy
23.41
5,000
117,050
6,000
Mahoney Stephen F.
President and CEO
Sep 27 '24
Buy
23.33
21,400
499,262
21,400
Fairmount Funds Management LLC
Director
Sep 13 '24
Buy
18.75
1,600,000
30,000,000
3,445,813
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
Kapitalisierung:     |  Volumen (24h):